These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

645 related items for PubMed ID: 11694787

  • 1. Interaction between Herceptin and taxanes.
    Diéras V, Beuzeboc P, Laurence V, Pierga JY, Pouillart P.
    Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
    [Abstract] [Full Text] [Related]

  • 2. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
    Baselga J.
    Oncology; 2001; 61 Suppl 2():14-21. PubMed ID: 11694783
    [Abstract] [Full Text] [Related]

  • 3. First-line Herceptin monotherapy in metastatic breast cancer.
    Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ.
    Oncology; 2001; 61 Suppl 2():37-42. PubMed ID: 11694786
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Role of Herceptin in primary breast cancer: views from North America and Europe.
    Leyland-Jones B, Smith I.
    Oncology; 2001; 61 Suppl 2():83-91. PubMed ID: 11694792
    [Abstract] [Full Text] [Related]

  • 6. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA.
    Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [Abstract] [Full Text] [Related]

  • 7. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
    Bullock K, Blackwell K.
    Oncologist; 2008 May; 13(5):515-25. PubMed ID: 18515736
    [Abstract] [Full Text] [Related]

  • 8. [Docetaxel (Taxotere) in combination with trastuzumab (Herceptin)].
    Ficorella C.
    Tumori; 2001 May; 87(1 Suppl 2):S10-8. PubMed ID: 11357872
    [No Abstract] [Full Text] [Related]

  • 9. HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
    Nabholtz JM, Reese DM, Lindsay MA, Riva A.
    Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S75-9. PubMed ID: 12435291
    [Abstract] [Full Text] [Related]

  • 10. Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study.
    Meden H, Beneke A, Hesse T, Novophashenny I, Wischnewsky M.
    Anticancer Res; 2001 Oct; 21(2B):1301-5. PubMed ID: 11396203
    [Abstract] [Full Text] [Related]

  • 11. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
    Slamon D, Pegram M.
    Semin Oncol; 2001 Feb; 28(1 Suppl 3):13-9. PubMed ID: 11301370
    [Abstract] [Full Text] [Related]

  • 12. Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer.
    Gori S, Colozza M, Mosconi AM, Franceschi E, Basurto C, Cherubini R, Sidoni A, Rulli A, Bisacci C, De Angelis V, Crinò L, Tonato M.
    Br J Cancer; 2004 Jan 12; 90(1):36-40. PubMed ID: 14710203
    [Abstract] [Full Text] [Related]

  • 13. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
    Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, Quan E, Crown J, Toppmeyer D, Smylie M, Riva A, Blitz S, Press MF, Reese D, Lindsay MA, Slamon DJ.
    J Natl Cancer Inst; 2004 May 19; 96(10):759-69. PubMed ID: 15150304
    [Abstract] [Full Text] [Related]

  • 14. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer.
    Burris HA.
    Semin Oncol; 2001 Feb 19; 28(1 Suppl 3):38-44. PubMed ID: 11301373
    [Abstract] [Full Text] [Related]

  • 15. Trials of new combinations of Herceptin in metastatic breast cancer.
    Thomssen C.
    Anticancer Drugs; 2001 Dec 19; 12 Suppl 4():S19-25. PubMed ID: 11989523
    [Abstract] [Full Text] [Related]

  • 16. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).
    Burris HA.
    Semin Oncol; 2000 Apr 19; 27(2 Suppl 3):19-23. PubMed ID: 10810934
    [Abstract] [Full Text] [Related]

  • 17. In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines.
    Merlin JL, Barberi-Heyob M, Bachmann N.
    Ann Oncol; 2002 Nov 19; 13(11):1743-8. PubMed ID: 12419746
    [Abstract] [Full Text] [Related]

  • 18. [Docetaxel (Taxotere) in combination with anthracycline, capecitabin (Xeloda) and new drugs].
    Galligioni E.
    Tumori; 2001 Nov 19; 87(1 Suppl 2):S1-9. PubMed ID: 11357871
    [No Abstract] [Full Text] [Related]

  • 19. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy.
    Fujimoto-Ouchi K, Sekiguchi F, Yamamoto K, Shirane M, Yamashita Y, Mori K.
    Cancer Chemother Pharmacol; 2010 Jul 19; 66(2):269-76. PubMed ID: 19904537
    [Abstract] [Full Text] [Related]

  • 20. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
    Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, Gelman R, Winer EP.
    Cancer; 2007 Sep 01; 110(5):965-72. PubMed ID: 17614302
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.